Description
Formulation:
Each vial of 100 mg contains:
Hydrocortisone, USP (as Sodium Succinate) 100 mg
Packaging/Availability:
USP Type II Glass Vial with Aluminum Seal, Rubber Stopper and Red Protective Cap x 1’s.
Hydrocortisone 100mg Lyophilized Powder for Injection (I.M./I.V.)
Hydrocortisone 100mg Lyophilized Powder for Injection (I.M./I.V.)
Formulation:
Each vial of 100 mg contains:
Hydrocortisone, USP (as Sodium Succinate) 100 mg
Packaging/Availability:
USP Type II Glass Vial with Aluminum Seal, Rubber Stopper and Red Protective Cap x 1’s.
Indications:
Treatment of adrenocortical insufficiency; shock, hypersensitivity reactions; inflammatory bowel disease, ulcerative colitis, proctitis, proctosigmoiditis and rheumatic disease.
See insert for complete information
Dosage and Administration
Hydrocortisone Sodium Succinate (Corticare) may be administered by intravenous injection, by intravenous infusion or by intramuscular injection, the preferred method for initial emergency use is intravenous injection. Therapy is initiated by administering Hydrocortisone Sodium Succinate (Corticare) Sterile Powder intravenously over a period of 30 seconds (e.g., Hydrocortisone sodium succinate equivalent to 100 mg of Hydrocortisone) to 10 minutes (e.g., 500 mg or more). In general, high-dose corticosteroid therapy should be continued until the patient’s condition has stabilized, usually not beyond 48 to 72 hours. Although adverse effects associated with high dose, short-term corticoid therapy are uncommon, peptic ulceration may occur. Prophylactic antacid therapy may be indicated. When high-dose Hydrocortisone therapy must be continued beyond 48 -72 hours, hypernatremia may occur. Under such circumstances It may be desirable to replace Hydrocortisone Sodium Succinate (Corticare) sterile powder with corticoid product such as one containing methylprednisolone sodium succinate which causes little or no sodium retention. The initial dose of Hydrocortisone Sodium Succinate (Corticare) Sterile Powder is 100 mg to 500 mg or more (hydrocortisone equivalent to hydrocortisone sodium Succinate) depending on the severity of the condition. This dose may be repeated at intervals of 2,4 or 6 hours as indicated by the patient’s responses and clinical condition. While the dose may be reduced for infants and children, it is governed more by the severity of the condition and response of the patient than by age or body weight, but should not be less than 25 mg daily. The maximum dose being 15 mg/kg. Patients subjected to severe stress following corticosteroid therapy should be observed closely for signs and symptoms of adrenocortical insufficiency. Corticosteroid therapy is an adjunct to, and not a replacement for
conventional therapy.
Exclusively Distributed by:
EURO-CARE PRODUCTS, PHILIPPINES
Tinio St., San Nicolas,
Gapan City, Nueva Ecija
Imported by:
SAHAR INTERNATIONAL TRADING INC.
354 Aguirre Ave., Phase III BF Homes,
Parañaque City
Manufactured by:
AMSON VACCINES & PHARMA (PVT) LTD.
Islamabad, Pakistan
Reviews
There are no reviews yet.